PPTA Twitter

PlasmaProteins #Plasma goes through a complex manufacturing process known as fractionation where proteins are separated to develop #plasmaprotein therapies. Learn more about the process: bit.ly/2ytTQCI pic.twitter.com/ZYK7nzwrvi
About 6 hours ago.
PlasmaProteins Next month, @PlasmaProteins will hold its annual Fly-In on Capitol Hill! PPTA, its membership, and stakeholders will advocate for patient protections & the importance of prohibitions on lifetime and annual caps for people who need #plasmaprotein therapies. bit.ly/2FRKqnR
1 day ago.

The U.S. Senate will try to move forward shortly on a “motion to proceed” to debate on repeal of the Affordable Care Act

PPTA is concerned that access to therapies and important protections for vulnerable patients with rare diseases will not be included in the Better Care Reconciliation Act (BCRA).  In an effort to end what they consider a failing exchange system, Senate Republicans are trying to garner enough votes to proceed to debate on repeal.

The draft versions of BCRA, with various amendments, would allow changes to the Essential Health Benefits that patients who use plasma protein therapies rely on. These include:

1. Prohibit lifetime and annual caps on coverage
2. Prohibit being denied coverage because of a pre-existing condition
3. Allow dependent children on their parents’ insurance until age 26
4. Limit maximum out of pocket costs for patients

Since access to plasma protein therapies to treat primary immunodeficiencies, alpha-1 antitrypsin deficiency, hereditary angioedema and bleeding disorders, such as hemophilia, is so vital to patient well-being, PPTA is telling Senators to vote NO on the current motion to proceed. The four patient protections must be included in whatever health care legislation moves forward in Congress.

 July 25, 2017

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100